What is the efficacy of riociguat for the treatment of pulmonary arterial hypertension (PAH)?

Updated: Apr 25, 2018
  • Author: Kristin E Schwab, MD; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print

Riociguat is the first sGC stimulator approved in the United States. It elicits a dual mode of action. It sensitizes sGC to endogenous nitric oxide by stabilizing the nitric oxide-sGC binding, and it directly stimulates sGC via a different binding site, independently of nitric oxide. It is indicated for CTEPH and PAH. Approval was based on data from the two randomized, double-blind, placebo-controlled, global phase III studies, CHEST-1 and PATENT-1. In each study, riociguat significantly improved exercise capacity and pulmonary vascular resistance in patients with PAH. [65, 66]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!